NO20073928L - Stabilt partikkelformig legemiddel med solifenacin eller salt av dette - Google Patents
Stabilt partikkelformig legemiddel med solifenacin eller salt av detteInfo
- Publication number
- NO20073928L NO20073928L NO20073928A NO20073928A NO20073928L NO 20073928 L NO20073928 L NO 20073928L NO 20073928 A NO20073928 A NO 20073928A NO 20073928 A NO20073928 A NO 20073928A NO 20073928 L NO20073928 L NO 20073928L
- Authority
- NO
- Norway
- Prior art keywords
- solifenacin
- salt
- particulate
- stable particulate
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Stabil partikkelformig farmasøytisk blanding av solifenacin eller salt derav for anvendelse som et farmasøytisk preparat på det kliniske område. Preparatet er i kuleform egnet for påføring av overtrekk, hvor degradering over tid kan bli inhibert, Det partikkelformige farmasøytiske preparat fremstilles ved å anvende et bindemiddel med Tg eller smp lavere enn 174 0C, ved formuleringen av en partikkelformig blanding med solifenacin til et farmasøytisk preparat. Det utføres behandling som påskynder krystallisasjon etter at den partikkelformige farmasøytiske blanding er dannet, og det oppnås en stabilere partikkelformig blanding med solifenacin eller et salt derav.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63838804P | 2004-12-27 | 2004-12-27 | |
JP2005085968 | 2005-03-24 | ||
PCT/JP2005/023771 WO2006070735A1 (ja) | 2004-12-27 | 2005-12-26 | ソリフェナシンまたはその塩の安定な粒子状医薬組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20073928L true NO20073928L (no) | 2007-09-18 |
Family
ID=36614852
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20073928A NO20073928L (no) | 2004-12-27 | 2007-07-26 | Stabilt partikkelformig legemiddel med solifenacin eller salt av dette |
Country Status (8)
Country | Link |
---|---|
US (1) | US20080103171A1 (no) |
EP (1) | EP1832288B1 (no) |
KR (1) | KR101342786B1 (no) |
CN (1) | CN101141961B (no) |
AU (1) | AU2005320672B2 (no) |
CA (1) | CA2591761A1 (no) |
NO (1) | NO20073928L (no) |
WO (1) | WO2006070735A1 (no) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100137358A1 (en) * | 1996-11-05 | 2010-06-03 | Dr. Reddy's Laboratories Ltd. | Solifenacin compositions |
WO2008128028A2 (en) * | 2007-04-11 | 2008-10-23 | Dr. Reddy's Laboratories Ltd. | Solifenacin compositions |
US20050175689A1 (en) * | 2003-10-27 | 2005-08-11 | Yamanouchi Pharmaceutical Co., Ltd. | Coated fine particles containing drug for intrabuccally fast disintegrating tablet |
KR101156406B1 (ko) * | 2004-03-25 | 2012-06-13 | 아스텔라스세이야쿠 가부시키가이샤 | 솔리페나신 또는 그의 염의 고형 제제용 조성물 |
CN101141961B (zh) * | 2004-12-27 | 2011-07-06 | 安斯泰来制药株式会社 | 索非那新或其盐的稳定的颗粒状药物组合物 |
US7815939B2 (en) * | 2005-07-20 | 2010-10-19 | Astellas Pharma Inc. | Coated fine particles containing drug for intrabuccally fast disintegrating dosage forms |
US8568785B2 (en) | 2006-07-19 | 2013-10-29 | Asahi Kasei Chemicals Corporation | Process for producing spherical base granule comprising easily water-soluble drug |
EP2018850A1 (en) * | 2007-07-24 | 2009-01-28 | Ratiopharm GmbH | Pharmaceutical composition comprising solifenacin or a pharmaceutically acceptable salt thereof |
PT2394648T (pt) | 2009-02-04 | 2016-10-03 | Astellas Pharma Inc | Composição farmacêutica para administração oral |
EP2415472A4 (en) * | 2009-03-30 | 2013-02-20 | Astellas Pharma Inc | SOLID PHARMACEUTICAL COMPOSITION WITH SOLUBENACIN AMORPHIC BODY |
EA201291189A1 (ru) | 2010-05-07 | 2013-05-30 | Зентива К.С. | Фармацевтическая композиция, содержащая солифенацин, и способ его получения |
BR112012029461A2 (pt) | 2010-05-19 | 2017-03-01 | Astellas Pharma Inc | composição farmacêutica contendo solifenacina |
SI2590973T1 (sl) | 2010-07-05 | 2017-01-31 | Crystal Pharma, S.A.U. | Soli solifenacina |
WO2012029838A1 (ja) * | 2010-08-31 | 2012-03-08 | 協和発酵キリン株式会社 | 口腔内崩壊錠 |
JP5936542B2 (ja) | 2010-09-01 | 2016-06-22 | アステラス製薬株式会社 | 包装体 |
EP2638039A1 (de) | 2010-11-11 | 2013-09-18 | Hexal AG | Kristallines solifenacin-succinat |
EP2500013B1 (en) | 2011-03-15 | 2019-10-02 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Pharmaceutical composition comprising solifenacin |
EP2778167A1 (en) | 2013-03-11 | 2014-09-17 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Stable pharmaceutical composition comprising amorphous solifenacin or its pharmaceutically acceptable salt |
KR20150092385A (ko) | 2014-02-03 | 2015-08-13 | 씨제이헬스케어 주식회사 | 솔리페나신을 포함하는 안정한 제제 및 이의 제조방법 |
JP2017078023A (ja) * | 2014-02-28 | 2017-04-27 | アステラス製薬株式会社 | 経口投与用医薬組成物 |
CN104940152B (zh) * | 2014-03-31 | 2017-12-29 | 成都国为生物医药有限公司 | 一种含有琥珀酸索利那新的药物组合物 |
JP2016079102A (ja) * | 2014-10-10 | 2016-05-16 | テバ製薬株式会社 | ソリフェナシン含有製剤 |
JP6805699B2 (ja) * | 2016-10-04 | 2020-12-23 | ニプロ株式会社 | 医薬組成物、医薬組成物の製造方法、及び非晶質体の安定性を向上させる方法 |
KR102090135B1 (ko) * | 2017-07-14 | 2020-03-17 | 주식회사 종근당 | 솔리페나신 또는 이의 약제학적으로 허용가능한 염을 포함하는 구강 붕해정 및 이의 제조방법 |
KR20210114271A (ko) | 2020-03-10 | 2021-09-23 | 주식회사 종근당 | 솔리페나신 또는 이의 약제학적으로 허용가능한 염을 함유하는 약제학적 조성물 |
WO2021220133A1 (en) * | 2020-04-27 | 2021-11-04 | Zim Laboratories Limited | Novel multiparticulate pharmaceutical composition of tamsulosin and solifenacin |
WO2022117594A1 (en) | 2020-12-01 | 2022-06-09 | Adamed Pharma S.A. | Orally-administered preparation containing solifenacin and tamsulosin |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8514665D0 (en) * | 1985-06-11 | 1985-07-10 | Eroceltique Sa | Oral pharmaceutical composition |
US4870059A (en) * | 1985-11-27 | 1989-09-26 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Dehydration of hydrous matter with anhydrous maltose |
US5082669A (en) * | 1989-07-20 | 1992-01-21 | Dainippon Pharmaceutical Co., Ltd. | Rapid-releasing oral particle pharmaceutical preparation with unpleasant taste masked |
US5075114A (en) * | 1990-05-23 | 1991-12-24 | Mcneil-Ppc, Inc. | Taste masking and sustained release coatings for pharmaceuticals |
US5260072A (en) * | 1990-08-30 | 1993-11-09 | Mcneil-Ppc, Inc. | Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets |
YU48263B (sh) * | 1991-06-17 | 1997-09-30 | Byk Gulden Lomberg Chemische Fabrik Gmbh. | Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola |
ES2056548T3 (es) * | 1991-09-25 | 1994-10-01 | Barilla Flli G & R | Barrita de pan que sabe como el pan y metodo de fabricarla. |
TW284688B (no) * | 1991-11-20 | 1996-09-01 | Takeda Pharm Industry Co Ltd | |
JP2682353B2 (ja) | 1991-11-20 | 1997-11-26 | 武田薬品工業株式会社 | 経口用医薬組成物およびその製造法 |
JPH0624001A (ja) | 1992-06-05 | 1994-02-01 | Nec Corp | インクカートリッジ及びこれを用いたインクジェット記録装置 |
US6011062A (en) * | 1994-12-22 | 2000-01-04 | Alcon Laboratories, Inc. | Storage-stable prostaglandin compositions |
NO2005012I1 (no) * | 1994-12-28 | 2005-06-06 | Debio Rech Pharma Sa | Triptorelin og farmasoytisk akseptable salter derav |
US5912268A (en) * | 1995-05-22 | 1999-06-15 | Alza Corporation | Dosage form and method for treating incontinence |
US5607697A (en) * | 1995-06-07 | 1997-03-04 | Cima Labs, Incorporated | Taste masking microparticles for oral dosage forms |
US20040136915A1 (en) * | 1997-10-01 | 2004-07-15 | Dugger Harry A. | Buccal, polar and non-polar spray containing atropine |
US6221402B1 (en) * | 1997-11-20 | 2001-04-24 | Pfizer Inc. | Rapidly releasing and taste-masking pharmaceutical dosage form |
US6465009B1 (en) * | 1998-03-18 | 2002-10-15 | Yamanouchi Pharmaceutical Co., Ltd. | Water soluble polymer-based rapidly dissolving tablets and production processes thereof |
ES2265439T3 (es) * | 2000-08-18 | 2007-02-16 | Pharmacia Corporation | Formulacion oral de valdecoxib que se desintegra rapidamente. |
US20020119196A1 (en) * | 2000-12-21 | 2002-08-29 | Narendra Parikh | Texture masked particles containing an active ingredient |
KR20030076634A (ko) * | 2001-01-30 | 2003-09-26 | 데이진 가부시키가이샤 | 의약 조성물 |
JP2004530676A (ja) * | 2001-04-18 | 2004-10-07 | ノストラム・ファーマスーティカルズ・インコーポレイテッド | 持続放出性薬学的組成物のための新規コーティング |
CA2447693A1 (en) * | 2001-05-31 | 2002-12-05 | Cima Labs Inc. | Taste-masking of highly water-soluble drugs |
DK1405638T3 (da) * | 2001-07-10 | 2011-04-18 | Astellas Pharma Inc | Farmaceutisk sammensætning omfattende quinuclidin-3'-yl-1-phenyl-1,2,3,4,-tetrahydroisoquinolin-2-carboxylat til behandling af interstitiel cystitis og/eller abakteriel prostatitis |
US20060035923A1 (en) * | 2002-06-07 | 2006-02-16 | Rian Van Meeteren | Overactive bladder treating drug |
MXPA05003398A (es) * | 2002-10-29 | 2005-06-22 | Pharmacia & Upjohn Co Llc | Compuestos de amonio cuaternario. |
JP4523265B2 (ja) * | 2002-11-13 | 2010-08-11 | 旭化成ファーマ株式会社 | 排尿障害治療用口腔内崩壊製剤 |
US20040184995A1 (en) * | 2003-03-17 | 2004-09-23 | Yamanouchi Pharmaceutical Co., Ltd. | Novel dry powder inhalation for lung-delivery and manufacturing method thereof |
DE602004003172T2 (de) * | 2003-03-21 | 2007-09-27 | Dynogen Pharmaceuticals Inc., Waltham | Verfahren zur behandlung von erkrankungen der unteren harnwege mit antimuskarinika und mit modulatoren der alpha-2-delta untereinheit des kalziumkanals |
US20060147531A1 (en) * | 2003-07-01 | 2006-07-06 | Mojca Segula | Tamsulosin core with a coating of polyvinylpyrrolidone and polyfinylacetate |
US20050175689A1 (en) * | 2003-10-27 | 2005-08-11 | Yamanouchi Pharmaceutical Co., Ltd. | Coated fine particles containing drug for intrabuccally fast disintegrating tablet |
RU2006127437A (ru) * | 2004-02-06 | 2008-03-20 | Вайет (Us) | Соли о-десметилвенлафаксина в виде дисперсных частиц и их применение |
WO2005077364A1 (ja) * | 2004-02-18 | 2005-08-25 | Yamanouchi Pharmaceutical Co., Ltd. | ソリフェナシンの経皮投与製剤およびその経皮透過改善方法 |
KR101156406B1 (ko) * | 2004-03-25 | 2012-06-13 | 아스텔라스세이야쿠 가부시키가이샤 | 솔리페나신 또는 그의 염의 고형 제제용 조성물 |
CN101141961B (zh) * | 2004-12-27 | 2011-07-06 | 安斯泰来制药株式会社 | 索非那新或其盐的稳定的颗粒状药物组合物 |
-
2005
- 2005-12-26 CN CN2005800450144A patent/CN101141961B/zh not_active Expired - Fee Related
- 2005-12-26 WO PCT/JP2005/023771 patent/WO2006070735A1/ja active Application Filing
- 2005-12-26 US US11/721,863 patent/US20080103171A1/en not_active Abandoned
- 2005-12-26 EP EP05820232A patent/EP1832288B1/en not_active Not-in-force
- 2005-12-26 AU AU2005320672A patent/AU2005320672B2/en not_active Ceased
- 2005-12-26 CA CA002591761A patent/CA2591761A1/en not_active Abandoned
-
2007
- 2007-07-26 KR KR1020077017266A patent/KR101342786B1/ko not_active IP Right Cessation
- 2007-07-26 NO NO20073928A patent/NO20073928L/no unknown
Also Published As
Publication number | Publication date |
---|---|
EP1832288A4 (en) | 2010-02-24 |
CN101141961A (zh) | 2008-03-12 |
US20080103171A1 (en) | 2008-05-01 |
EP1832288B1 (en) | 2012-06-20 |
KR101342786B1 (ko) | 2013-12-19 |
EP1832288A1 (en) | 2007-09-12 |
KR20070098889A (ko) | 2007-10-05 |
AU2005320672B2 (en) | 2011-01-06 |
WO2006070735A1 (ja) | 2006-07-06 |
CA2591761A1 (en) | 2006-07-06 |
CN101141961B (zh) | 2011-07-06 |
AU2005320672A1 (en) | 2006-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20073928L (no) | Stabilt partikkelformig legemiddel med solifenacin eller salt av dette | |
NO20063620L (no) | Arylanilinderivater som beta2 adrenergiske receptoragonister | |
WO2009066152A3 (en) | Haloallylamine inhibitors of ssao/vap-1 and uses therefor | |
MX2021000482A (es) | Composiciones de fenfluramina y métodos de preparación de las mismas. | |
NO20081325L (no) | Nye doseringsformuleringer | |
UY30183A1 (es) | Derivados de quinolina | |
DK2041133T3 (da) | Derivater af imadazol [1,2-A] pyridine-2-carboxamider, fremstilling deraf og anvendelse deraf i terapeutik | |
RS52169B (en) | STABLE LAKVINIMOD PREPARATIONS | |
RS20070076A (en) | Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases | |
NO20073959L (no) | Kinazolinderivat, fremgangsmate for fremstilling og anvendelse derav for inhibering av vekst av kreftceller | |
NO20100301L (no) | Forbedrete brimonidinsammensetninger for behandling av erytem | |
SE0401971D0 (sv) | Piperidne derivatives | |
RU2010116863A (ru) | Бупропиона гидробромид и его терапевтические применения | |
DK1856090T3 (da) | Substituerede thiophen-derivater som glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser | |
BRPI0515860A (pt) | derivados de tetralin e indano, e uso dos mesmos | |
DK1778680T3 (da) | Spirocykliske cyclohexaderivater | |
ATE459619T1 (de) | Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung | |
ITBO20110012A1 (it) | Composizioni farmaceutiche comprendenti rifaximina e loro uso. | |
DE602006015509D1 (de) | Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung | |
WO2005072132A3 (en) | TRICYCLIC MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-κB ACTIVITY AND USE THEREOF | |
WO2017062468A8 (en) | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof | |
WO2009140341A3 (en) | Atorvastatin compositions | |
DK1869038T3 (da) | Substituerede 5,6,7,8-tetrahydro-imidazol[1,2-a]pyridin-2-ylamin-forbindelser og deres anvendelse til fremstilling af lægemidler | |
MX2010009395A (es) | Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y procesos para preparacion de los mismos. | |
CL2009001267A1 (es) | Compuestos derivados de triciclos nitrogenados, con actividad antibacteriana; procedimiento de preparacion; composicion farmceutica que los comprende; para el tratamiento de la tuberculosis. |